Lifecore Biomedical (MM)【LCBM】株式ニュース

Lifecore Biomedical Reports Results for First Quarter Ended September 30, 2007

Maintains FY 2008 Guidance

LIFECORE BIOMEDICAL, INC. (Nasdaq:LCBM) today reported net sales of $15.7 million in the first quarter ended September 30, 2007, an increase of 5 percent over net sales of $15.0 million in the first quarter of fiscal year 2007. Foreign currency translation comparisons increased current quarter sales by $184,000 compared to the first quarter of last fiscal year.

Net income of $1,263,000, or $.09 per diluted share, was posted for the quarter compared to net income of $1,139,000, or $.08 per diluted share, in the quarter ended September 30, 2006. Income tax expense was recorded for the first quarter at an annual effective rate of 39.0% compared to an effective rate of 38.5% in the first quarter a year ago.

“Profits for the quarter were at the high-end of our guidance, although sales were slightly below,” said Dennis J. Allingham, President and CEO. “The results reflect our focus towards strengthening our Dental sales performance, while driving the continued operating efficiency from the Hyaluronan Division.”

The Company reported a cash and cash equivalents balance of $39.6 million at September 30, 2007. Cash effects associated with the income tax expenses reflected in the first quarter operating results were minimal due to the utilization of the net operating loss carry forwards.

Hyaluronan Division

Net sales from the Hyaluronan Division for the first quarter were $4.8 million; comparable to the sales reported in the same quarter last year.

The Division reported operating income of $943,000 in the first quarter compared to operating income of $996,000 in the first quarter of fiscal year 2007. The slight decline resulted from additional costs associated with product development.

“Higher sales to orthopedic customers and increased revenues from product development were partially offset by lower sales to ophthalmic customers,” said Dennis J. Allingham, President & CEO. “We are proceeding with our program to develop the Cleveland Clinic technology for long-term growth, while driving other development opportunities in existing segments as the interim growth vehicle.”

Dental Division

Net sales from the Dental Division for the first quarter were $10.8 million, an increase of 6% from the $10.2 million recorded in the first quarter last year. Foreign currency translation comparisons increased first quarter sales by $184,000. Domestic sales grew 9% for the quarter. Variability in distributor purchasing patterns resulted in little International sales growth for the quarter.

The Division reported operating income of $614,000 for the first quarter compared to operating income of $510,000 in the first quarter of fiscal year 2007.

“Sales of the Prima™ Implant System continued to drive sales growth with a significant 70% increase from the first quarter a year ago,” said Dennis J. Allingham, President & CEO. “Overall, we were pleased to see that actions taken improved the rate of sales growth, when compared to the fourth quarter of last fiscal year, particularly domestic sales. We expect to build on this momentum with the introduction of our Prima Ceramic abutment system, which was just cleared for the US market.”

Outlook

The Company is maintaining its guidance and expects fiscal year 2008 sales of $76.5 to $78.5 million, an increase of 10 to 13 percent over fiscal year 2007. Earnings per diluted share of $.56 to $.60 are expected.

The Company expects sales of $18.0 to $18.5 million in the second quarter of fiscal year 2008 with earnings per diluted share of $.10 to $.12. This guidance reflects an annual effective tax rate of 39.0% and stock option expense of $266,000.

The Company expects second quarter growth to be driven by both Divisions.

Conference Call

As previously announced, the Company will host a conference call today at 3:45 p.m. Central Time to discuss first quarter results. A live web cast of the call is available through the Company’s website at www.lifecore.com. After selecting the INVESTOR INFO tab, select CALENDAR OF EVENTS from the INVESTOR INFO & RESEARCH menu at the right side of the page and follow the instructions for participation. A replay of the web cast will be available shortly after completion of the call. To select the archived replay, select AUDIO ARCHIVES from the INVESTOR INFO & RESEARCH tools menu at the right side of the screen. The conference call will also be available at www.earnings.com.

The conference call may include forward-looking statements. See the cautionary information about such statements in the “Safe-Harbor Statement” section below.

Safe-Harbor Statement

Certain statements in this release regarding Lifecore’s anticipated future sales and financial results are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Numerous risks and uncertainties may affect whether such results are actually achieved. These include the timing of orders from customers, continued market acceptance of the Company’s products, effectiveness of the dental sales force expansion, timing of regulatory approvals, success of new product development efforts, the likelihood and timing of the return of the Company’s adhesion prevention product to the market, and other factors. These risks and uncertainties are more fully described in the Company’s Annual Report on Form 10-K for the fiscal year ending June 30, 2007, and other more recent filings. Actual results may differ materially from anticipated results.

About Lifecore Biomedical

Lifecore Biomedical, in business over 40 years, develops, manufactures, and markets biomaterials and medical devices for use in various surgical markets.

News and general information are available through the Company’s website at www.lifecore.com.
Lifecore Biomedical, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
September 30, June 30,
2007 2007
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 39,554,000 $ 39,105,000
Accounts receivable 16,185,000 15,555,000
Inventories 13,151,000 12,145,000
Deferred income taxes, net 3,035,000 3,684,000
Prepaid expense 1,468,000 1,448,000
Total current assets 73,393,000 71,937,000

PROPERTY, PLANT AND EQUIPMENT, NET 22,885,000 23,105,000

LONG-TERM INVENTORY 1,376,000 1,491,000
OTHER ASSETS 5,728,000 5,738,000
$ 103,382,000 $ 102,271,000

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities $ 6,822,000 $ 7,323,000
Long-term obligations 4,424,000 4,496,000
Long-term tax reserve 584,000 -
Long-term deferred income taxes, net 982,000 982,000
Shareholders' equity 90,570,000 89,470,000
$ 103,382,000 $ 102,271,000
Lifecore Biomedical, Inc.
Consolidated Statements of Operations
(Unaudited)

Three Months Ended
September 30,
2007 2006

Net sales $ 15,683,000 $ 15,010,000
Cost of goods sold 5,982,000 5,572,000
Gross profit 9,701,000 9,438,000

Operating expenses
Research and development 1,240,000 1,096,000
Marketing and sales 4,828,000 4,912,000
General and administrative 2,076,000 1,924,000
8,144,000 7,932,000

Operating income 1,557,000 1,506,000

Other income (expense)
Interest income 496,000 331,000
Interest expense (68,000 ) (64,000 )
Currency transaction gains 54,000 73,000
Other 31,000 6,000
513,000 346,000

Income before income taxes 2,070,000 1,852,000

Income tax expense 807,000 713,000

Net Income $ 1,263,000 $ 1,139,000

Net income per share
Basic $ 0.09 $ 0.09
Diluted $ 0.09 $ 0.08

Weighted average shares outstanding
Basic 13,472,018 13,223,448
Diluted 13,798,491 13,672,260
Lifecore Biomedical, Inc.
Divisional Statements of Operations
Three Months Ended September 30,
(Unaudited)

Hyaluronan Division Dental Division Consolidated
2007 2006 2007 2006 2007 2006

Net sales $ 4,849,000 $ 4,779,000 $ 10,834,000 $ 10,231,000 $ 15,683,000 $ 15,010,000
Cost of goods sold 2,084,000 2,122,000 3,898,000 3,450,000 5,892,000 5,572,000
Gross profit 2,765,000 2,657,000 6,956,000 6,781,000 9,701,000 9,438,000

Operating expenses
Research and development 888,000 716,000 352,000 380,000 1,240,000 1,096,000
Marketing and sales 118,000 196,000 4,710,000 4,716,000 4,828,000 4,912,000
General and administrative 816,000 749,000 1,260,000 1,175,000 2,076,000 1,924,000
1,822,000 1,661,000 6,322,000 6,271,000 8,144,000 7,932,000

Operating income $

943,000
$ 996,000 $

614,000
$

510,000
$ 1,577,000 $ 1,506,000

Lifecore Biomedical, Inc.
Dennis J. Allingham, 952-368-4300
President and CEO
or
David M. Noel, 952-368-4300
Vice President of Finance and CFO

Lifecore Biomedical Reports Results for Fourth Quarter and Fiscal Year Ended June 30, 2007

Meets Fourth Quarter and Annual Guidance

LIFECORE BIOMEDICAL, INC. (NASDAQ:LCBM) today reported record net sales of $19.2 million in the fourth quarter ended June 30, 2007, an increase of 9% over net sales of $17.7 million in the fourth quarter of fiscal year 2006. Foreign currency translation comparisons increased current quarter sales by $203,000 compared to the fourth quarter of last fiscal year.

Net income of $2,881,000, or $.21 per diluted share, was posted for the quarter compared to net income of $2,411,000, or $.18 per diluted share, in the quarter ended June 30, 2006. Income tax expense was recorded for the fourth quarter at an annual effective rate of 38.5% compared to an annual effective rate of 39.7% in the quarter a year ago.

For its fiscal year ended June 30, 2007, Lifecore had record net sales of $69.6 million, an increase of 10% over the $63.1 million reported in fiscal year 2006. Foreign currency translation comparisons increased fiscal 2007 sales by $790,000 compared to fiscal 2006.

Fiscal 2007 net income was $7,719,000, or $.56 per diluted share, compared to fiscal 2006 net income of $7,040,000, or $.52 per diluted share. Fiscal year results include expenses for stock options in the amount of $1,191,000 and $844,000 for 2007 and 2006, respectively. Income tax expense was recorded for fiscal 2007 at an annual effective rate of 38.6% compared to an effective rate of 38.4% for fiscal 2006.

“Record sales and earnings were recorded for the third year in a row,” said Dennis J. Allingham, President and CEO. “The Hyaluronan Division posted another strong quarterly performance and sales of the Prima™ Implant System increased 107% in the fourth quarter compared to the same quarter a year ago.

The Company’s cash and cash equivalents position is $39.1 million at June 30, 2007, an increase of $12.5 million from last fiscal year. Cash effects associated with the income tax expenses reflected in the operating results were minimal due to the utilization of net operating loss carry forwards.

Hyaluronan Division

Net sales from the Hyaluronan Division for the fourth quarter were a record $6.3 million, an increase of 14% from the $5.5 million reported in the same quarter last year. Net sales for fiscal year 2007 were also a record at $21.6 million compared to $20.2 million a year ago, an increase of $1.4 million or 7%. Growth in the quarter and the fiscal year resulted from higher sales to ophthalmic customers and increased revenue from customers conducting product development. Fiscal year growth also was attributed to increased revenue from orthopedic customers.

The Division reported operating income of $2,170,000 for the fourth quarter compared to operating income of $1,737,000 in the fourth quarter of fiscal year 2006. Operating income of $5,237,000 was reported for fiscal year 2007, which was comparable to operating income of $5,284,000 last fiscal year.

“Despite increased investment in product development, the leverage from record sales and a favorable product mix drove operating income to a record level of 34% of net sales in the fourth quarter and to 24% of net sales for the fiscal year,” said Dennis J. Allingham, President & CEO. “We are pleased with our ability to improve operating profitability despite making the product development investment that is critical to our future growth.”

Dental Division

Net sales from the Dental Division for the quarter were a record $12.9 million, an increase of 6% from the $12.2 million recorded in the fourth quarter last year. Net sales for fiscal year 2007 were a record $48.1 million compared to $42.9 million in fiscal year 2006, an increase of 12%. Foreign currency translation comparisons increased fourth quarter and fiscal 2007 sales by $203,000 and $790,000, respectively. Domestic sales were up slightly in the fourth quarter and increased 11% for the fiscal year. International sales increased 13% in both the fourth quarter and the fiscal year.

The Division reported operating income of $2,127,000 for the fourth quarter compared to operating income of $1,943,000 in the fourth quarter of fiscal year 2006. Operating income of $5,914,000 was reported for the fiscal year compared to operating income of $5,592,000 in fiscal year 2006.

“Sales of the Prima™ Implant System now represent over 28% of dental sales,” said Dennis J. Allingham, President & CEO. “Our Prima™ product portfolio continues to gain momentum as we expand our product offering and implement practice building strategies; both of which are designed to address the immediate and future needs of our target audience.”

Outlook

The Company expects fiscal year 2008 sales of $76.5 to $78.5 million, which represents an increase of 10 to 13 percent over fiscal year 2007.

Fiscal year 2008 growth is expected to be driven primarily by the Dental Division with increases in both domestic and international markets. Growth for the Hyaluronan Division is expected to be modest as we continue product development for future sales.

The Company is investing for the future growth of both Divisions. Included in FY 2008 guidance is more than a $2 million increase in development expenses associated with the technology licensed from Cleveland Clinic and for enhancements to dental product offerings. Fiscal 2008 earnings per share are expected to be $.56 to $.60 per diluted share, using a tax rate of 38.5%. The Company also noted that fiscal year 2008 guidance reflects stock option expenses of $1.1 million.

The Company expects sales of $15.8 to $16.2 million in the first quarter of fiscal year 2008 with earnings per diluted share of $.07 to $.09, using a tax rate of 38.5%. This guidance reflects stock option expense of $275,000.

Conference Call

As previously announced, the Company will host a conference call today at 3:45 p.m. Central Time to discuss fourth quarter and year-end results. A live web cast of the call is available through the Company’s website at www.lifecore.com. After selecting the INVESTOR INFO tab, select CALENDAR OF EVENTS from the INVESTOR INFO & RESEARCH menu at the right side of the page and follow the instructions for participation. A replay of the web cast will be available shortly after completion of the call. To select the archived replay, select AUDIO ARCHIVES from the INVESTOR INFO & RESEARCH tools menu at the right side of the screen. The conference call will also be available at www.earnings.com.

The conference call may include forward-looking statements. See the cautionary information about such statements in the “Safe-Harbor Statement” section below.

Safe-Harbor Statement

Certain statements in this release regarding Lifecore’s anticipated future sales and financial results are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Numerous risks and uncertainties may affect whether such results are actually achieved. These include the timing of orders from customers, continued market acceptance of the Company’s products, effectiveness of the dental sales force expansion, timing of regulatory approvals, success of new product development efforts, the likelihood and timing of the return of the Company’s adhesion prevention product to the market, and other factors. These risks and uncertainties are more fully described in the Company’s Annual Report on Form 10-K for the fiscal year ending June 30, 2006, and other more recent filings. Actual results may differ materially from anticipated results.

About Lifecore Biomedical

Lifecore Biomedical, in business over 40 years, develops, manufactures, and markets biomaterials and medical devices for use in various surgical markets.

News and general information are available through the Company’s website at www.lifecore.com.
Lifecore Biomedical, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
June 30, June 30,
2007 2006
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 39,105,000 $ 26,638,000
Accounts receivable 15,555,000 12,564,000
Inventories 12,145,000 12,217,000
Deferred income taxes, net 3,684,000 4,865,000
Prepaid expense 1,448,000 1,084,000
Total current assets 71,937,000 57,368,000

PROPERTY, PLANT AND EQUIPMENT, NET 23,105,000 23,250,000

LONG-TERM INVENTORY 1,491,000 1,406,000
DEFERRED INCOME TAXES, NET -- 1,694,000
OTHER ASSETS

5,738,000
5,520,000
$ 102,271,000 $ 89,238,000

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities $ 7,323,000 $ 6,898,000
Long-term obligations 4,496,000 4,804,000
Long-term deferred income taxes, net 982,000 --
Shareholders' equity 89,470,000 77,536,000
$ 102,271,000 $ 89,238,000
Lifecore Biomedical, Inc.
Consolidated Statements of Operations
(Unaudited)

Three Months Ended Twelve Months Ended
June 30, June 30,
2007 2006 2007 2006

Net sales $ 19,202,000 $ 17,688,000 $ 69,629,000 $ 63,097,000
Cost of goods sold 6,749,000 6,493,000 26,008,000 23,892,000
Gross profit 12,453,000 11,195,000 43,621,000 39,205,000

Operating expenses
Research and development 1,248,000 936,000 4,630,000 3,814,000
Marketing and sales 4,972,000 4,793,000 20,251,000 17,454,000
General and administrative 1,936,000 1,786,000 7,589,000 7,061,000
8,156,000 7,515,000 32,470,000 28,329,000

Operating income 4,297,000 3,680,000 11,151,000 10,876,000

Other income (expense)
Interest income 437,000 258,000 1,515,000 753,000
Interest expense (68,000 ) (70,000 ) (269,000 ) (251,000 )
Currency transaction gains (losses) 2,000 98,000 158,000 25,000
Other 13,000 31,000 24,000 17,000
384,000 317,000 1,428,000 544,000

Income before income tax expense 4,681,000 3,997,000 12,579,000 11,420,000

Income tax expense 1,800,000 1,586,000 4,860,000 4,380,000

Net Income $ 2,881,000 $ 2,411,000 $ 7,719,000 $ 7,040,000

Net income per share
Basic $ 0.21 $ 0.18 $ 0.58 $ 0.54
Diluted $ 0.21 $ 0.18 $ 0.56 $ 0.52

Weighted average shares outstanding
Basic 13,421,200 13,195,771 13,322,077 13,149,611
Diluted 13,886,966 13,652,548 13,783,743 13,561,852
Lifecore Biomedical, Inc.
Divisional Statements of Operations
Three Months Ended June 30,
(Unaudited)

Hyaluronan Division Dental Division Consolidated
2007 2006 2007 2006 2007 2006

Net sales $ 6,309,000 $ 5,513,000 $ 12,893,000 $ 12,176,000 $ 19,202,000 $ 17,688,000
Cost of goods sold 2,424,000 2,346,000 4,325,000 4,147,000 6,749,000 6,493,000
Gross profit 3,885,000 3,166,000 8,568,000 8,029,000 12,453,000 11,195,000

Operating expenses
Research and development 936,000 573,000 312,000 363,000 1,248,000 936,000
Marketing and sales 89,000 237,000 4,883,000 4,556,000 4,972,000 4,793,000
General and administrative 690,000 619,000 1,246,000 1,167,000 1,936,000 1,786,000
1,715,000 1,429,000 6,441,000 6,086,000 8,156,000 7,515,000

Operating income $ 2,170,000 $ 1,737,000 $ 2,127,000 $ 1,943,000 $ 4,297,000 $ 3,680,000
Lifecore Biomedical, Inc.
Divisional Statements of Operations
Twelve Months Ended June 30,
(Unaudited)

Hyaluronan Division Dental Division Consolidated
2007 2006 2007 2006 2007 2006

Net sales $ 21,552,000 $ 20,151,000 $ 48,077,000 $ 42,946,000 $ 69,629,000 $ 63,097,000
Cost of goods sold 9,568,000 9,204,000 16,440,000 14,688,000 26,008,000 23,892,000
Gross profit 11,984,000 10,947,000 31,637,000 28,258,000 43,621,000 39,205,000

Operating expenses
Research and development 3,220,000 2,301,000 1,410,000 1,513,000 4,630,000 3,814,000
Marketing and sales 680,000 670,000 19,571,000 16,784,000 20,251,000 17,454,000
General and administrative 2,847,000 2,692,000 4,742,000 4,369,000 7,589,000 7,061,000
6,747,000 5,663,000 25,723,000 22,666,000 32,470,000 28,329,000

Operating income $ 5,237,000 $ 5,284,000 $ 5,914,000 $ 5,592,000 $ 11,151,000 $ 10,876,000

Lifecore Biomedical, Inc.
Dennis J. Allingham, 952-368-4300
President and CEO
or
David M. Noel, 952-368-4300
Vice President of Finance and CFO

Source: Business Wire (August 14, 2007 - 3:05 PM EST)

News by QuoteMedia
www.quotemedia.co